Generic Fruzaqla Availability
Last updated on Apr 10, 2025.
Fruzaqla is a brand name of fruquintinib, approved by the FDA in the following formulation(s):
FRUZAQLA (fruquintinib - capsule;oral)
Is there a generic version of Fruzaqla available?
No. There is currently no therapeutically equivalent version of Fruzaqla available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fruzaqla. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
Patent 10,519,142
Issued: December 31, 2019
Inventor(s): Wu Zhenping & Li Wenji & Chu Yuping
Assignee(s): HUTCHISON MEDIPHARMA LIMITEDThe present invention relates to the pharmaceutical field, provides novel crystalline forms, solvates and the crystalline forms thereof of compound 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide, pharmaceutical compositions, as well as the methods of preparation and the use thereof.
Patent expiration dates:
- September 7, 2035✓✓✓
- September 7, 2035
-
Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
Patent 11,046,674
Issued: June 29, 2021
Inventor(s): Wu Zhenping & Li Wenji & Chu Yuping
Assignee(s): HUTCHISON MEDIPHARMA LIMITEDCrystalline forms of compound 6-(6,7-dimethoxyquinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide, pharmaceutical compositions and the methods of preparation and the use thereof.
Patent expiration dates:
- September 7, 2035✓
- September 7, 2035
-
Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
Patent 7,829,574
Issued: November 9, 2010
Inventor(s): Su; Wei-Guo et al.
Assignee(s): Hutchison MediPharma Enterprises Limited (N/A, BS)Substituted quinazoline compounds of the following formula: ##STR00001## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, and X are defined herein. It also discloses a pharmaceutical composition containing one of these compounds.
Patent expiration dates:
- May 9, 2028✓✓
- May 9, 2028
-
Use of substituted quinazoline compounds in treating angiogenesis-related diseases
Patent 8,212,033
Issued: July 3, 2012
Inventor(s): Su Wei-Guo & Zhang Weihan & Yan Xiaoqiang & Cui Yumin & Ren Yongxin & Duan Jifeng
Assignee(s): Hutchison Medipharma Enterprises LimitedQuinazoline derivatives of the following formula:
Patent expiration dates:
- May 9, 2028✓
- May 9, 2028
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- November 8, 2028 - NEW CHEMICAL ENTITY
More about Fruzaqla (fruquintinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
